Contributing factors for HIV-associated wasting have been identified across a number of physiological systems.

The people depicted on this website are not actual HIV-associated wasting patients or healthcare professionals.

Learn more about a specific treatment option for HIV-associated wasting.


  1. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther. 2007;29(11):2269-2288.
  2. Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Med. 2006;7(5):299-310.
  3. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Natur Rev. 2015;14:58-74
  4. Chereshnev VA, Bocharov G, Bazhan S, et al. Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective. Int Rev Immunol. 2013;32(3):282-306.
  5. Atfeld M, Gale M. Innate immunity against HIV-1 infection. Nature Immunol. 2015;16(6):554-562.
  6. Koethe JR, Heimburger DC, PrayGod G, Filteau S. From wasting to obesity: the contribution of nutritional status to immune activation in HIV infection. J Infec Dis. 2016;214(suppl 2):S75-S82.
  7. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV Aids Rep. 2007;4(1):10-15.
  8. Márquez M, Fernández Gutiérrez del Álamo C, Girón-González JA. Gut epithelial barrier dysfunction in human immunodeficiency cirus-hepatitis C virus coinfected patients: influence on innate and acquired immunity. World J Gastroenterol. 2016;22(4):1433-1448.